Alltrna's ML-driven platform optimizes sequence and modifications from natural tRNAs to significantly increase premature termination codon (PTC) readthrough First Alltrna-engineered tRNA ...
For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...
Alltrna's ML-driven platform has screened billions of tRNA molecules in silico to precisely engineer therapeutic properties driven by tRNA sequence and chemical modifications Alltrna presents data ...
Alltrna is advancing a new class of genetic medicines based on the power of tRNA biology to universally treat Stop Codon Disease, which encompasses thousands of genetic diseases caused by a premature ...
A research paper published in the journal Cell Metabolism by the team of Prof. Liu Qiang at the University of Science and Technology of China (USTC) reveals the critical role of glutamate tRNA ...
Ribonucleic acid (RNA) molecules are present in all living cells, with different types of RNA having different jobs. For example, messenger RNA is copied from DNA and carries instructions on how to ...
Alltrna has raised another $109 million in a series B to fund the Flagship Pioneering biotech's mission to "stop codon disease" with potential benefits for a range of genetic diseases caused by ...
tRNAs have a distinct cloverleaf secondary structure and an L-shaped tertiary structure. The cloverleaf structure is formed by the folding of the single-stranded tRNA molecule, which is typically ...
The various identities of cells, whether they are in the brain, heart, kidney, or any other tissue, are defined by the genes they expressed. In basic terms, the genes that are active in a cell are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results